8-KEarnings & ResultsExhibits & Filings

AbbVie Inc. 8-K Report, Financial Results (Jan 29, 2016)

Filed January 29, 2016For Securities:ABBV

Summary

AbbVie Inc. (ABBV) filed an 8-K report on January 29, 2016, to announce its financial results for the fourth quarter and full year ended December 31, 2015. The primary purpose of this filing is to provide investors with timely information regarding the company's performance, as detailed in the press release furnished as Exhibit 99.1. This report signifies that AbbVie has disclosed its latest financial figures, which are crucial for investors to assess the company's profitability, operational efficiency, and overall financial health. The press release accompanying this 8-K would contain key metrics such as revenue, earnings per share (EPS), and potentially segment-specific performance, offering insights into the company's strategic execution and market position as of the end of 2015.

Key Highlights

  • 1AbbVie Inc. (ABBV) released its Q4 and full-year 2015 financial results on January 29, 2016, via an 8-K filing.
  • 2The filing includes a press release as Exhibit 99.1, detailing the financial performance for the periods ending December 31, 2015.
  • 3This report is crucial for investors to evaluate AbbVie's operational and financial standing at the close of the 2015 fiscal year.
  • 4The disclosed financial results provide insights into revenue, profitability, and other key performance indicators.
  • 5The Chief Financial Officer, William J. Chase, signed the report, underscoring the significance of the financial disclosures.

Frequently Asked Questions

The main purpose of this 8-K filing is to publicly announce and provide investors with AbbVie Inc.'s financial results for the fourth quarter and the full fiscal year ended December 31, 2015. The detailed results are contained within a press release furnished as an exhibit to this report.

The detailed financial results are located in the press release furnished as Exhibit 99.1 to this 8-K filing. This press release contains the specific financial data for the fourth quarter and full year 2015.

The report is signed by William J. Chase, who is AbbVie Inc.'s Executive Vice President and Chief Financial Officer, indicating his responsibility for the accuracy and completeness of the disclosed financial information.